Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IKNA Stock Summary
Top 10 Correlated ETFs
IKNA
In the News
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Ikena Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen's 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023.
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.47 per share a year ago.
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?
Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.
Ikena Oncology to Participate in Spring 2022 Investor Conferences
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.
IKNA Financial details
IKNA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.98 | 0.27 | 1.11 | 0.43 | 0.22 | |
Net income per share | -1.2 | -1.28 | -1.22 | -1.84 | -1.63 | |
Operating cash flow per share | 3.43 | -1.09 | -2.15 | -2.05 | -1.91 | |
Free cash flow per share | 3.4 | -1.12 | -2.22 | -2.09 | -1.92 | |
Cash per share | 5.87 | 4.7 | 8.3 | 4.34 | 4.2 | |
Book value per share | -4.39 | -2.92 | 7.43 | 4.06 | 4.07 | |
Tangible book value per share | -4.39 | -2.92 | 7.43 | 4.06 | 4.07 | |
Share holders equity per share | -4.39 | -2.92 | 7.43 | 4.06 | 4.07 | |
Interest debt per share | 5.82 | 5.96 | 0.25 | 0.22 | 0.26 | |
Market cap | 447.6M | 1.11B | 350.91M | 96.26M | 82.22M | |
Enterprise value | 444.39M | 944.51M | 125.68M | 42.04M | -26.94M | |
P/E ratio | -26.62 | -25.01 | -10.29 | -1.44 | -1.21 | |
Price to sales ratio | 32.55 | 120.38 | 11.33 | 6.16 | 8.98 | |
POCF ratio | 9.34 | -29.26 | -5.82 | -1.3 | -1.03 | |
PFCF ratio | 9.4 | -28.68 | -5.66 | -1.27 | -1.03 | |
P/B Ratio | -7.28 | -10.95 | 1.69 | 0.65 | 0.48 | |
PTB ratio | -7.28 | -10.95 | 1.69 | 0.65 | 0.48 | |
EV to sales | 32.31 | 102.73 | 4.06 | 2.69 | -2.94 | |
Enterprise value over EBITDA | -24.35 | -21.36 | -3.74 | -0.6 | 0.36 | |
EV to operating cash flow | 9.27 | -24.97 | -2.09 | -0.57 | 0.34 | |
EV to free cash flow | 9.33 | -24.47 | -2.03 | -0.56 | 0.34 | |
Earnings yield | -0.04 | -0.04 | -0.1 | -0.69 | -0.83 | |
Free cash flow yield | 0.11 | -0.03 | -0.18 | -0.78 | -0.97 | |
Debt to equity | -1.32 | -2.04 | 0.03 | 0.04 | 0.06 | |
Debt to assets | 0.95 | 1.22 | 0.03 | 0.03 | 0.06 | |
Net debt to EBITDA | 0.18 | 3.67 | 6.7 | 0.77 | 1.47 | |
Current ratio | 3.51 | 5.86 | 8.7 | 7.44 | 12.58 | |
Interest coverage | 0 | 0 | 0 | -32.99 | 0 | |
Income quality | -2.85 | 0.85 | 1.77 | 1.08 | 1.17 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.53 | 0.96 | 0.58 | 1.42 | 2.72 | |
Research and developement to revenue | 1.81 | 4.88 | 1.52 | 4.12 | 6.4 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.01 | 0.02 | 0.03 | 0.02 | 0.01 | |
Capex to revenue | -0.02 | -0.08 | -0.06 | -0.09 | -0.05 | |
Capex to depreciation | -1.3 | -2.55 | -3.24 | -1.91 | -0.41 | |
Stock based compensation to revenue | 0.08 | 0.2 | 0.17 | 0.48 | 0.83 | |
Graham number | 10.9 | 9.17 | 14.27 | 12.97 | 12.23 | |
ROIC | -0.93 | -0.42 | -0.15 | -0.43 | -0.4 | |
Return on tangible assets | -0.2 | -0.26 | -0.14 | -0.39 | -0.35 | |
Graham Net | -4.67 | -3.09 | 6.87 | 3.64 | 3.67 | |
Working capital | 60.91M | 137.64M | 209.33M | 138.51M | 164.46M | |
Tangible asset value | -61.46M | -101.05M | 207.88M | 146.97M | 169.76M | |
Net current asset value | -62.23M | -103.48M | 196.51M | 134.72M | 156.33M | |
Invested capital | -1.32 | -2.04 | 0.03 | 0.04 | 0.06 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 1.53M | 2.25M | 2.24M | 2.08M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 13.68 | 17.27 | 18.47 | 375.59 | 739.3 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 26.67 | 21.13 | 19.76 | 0.97 | 0.49 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.27 | 0.44 | -0.16 | -0.45 | -0.4 | |
Capex per share | -0.02 | -0.02 | -0.06 | -0.04 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.15 | 0.15 | 0.05 | 0.03 | 0.01 | |
Net income per share | -0.36 | -0.36 | -0.44 | -0.4 | -0.41 | |
Operating cash flow per share | -0.49 | -0.55 | -0.46 | -0.46 | -0.46 | |
Free cash flow per share | -0.49 | -0.55 | -0.46 | -0.46 | -0.46 | |
Cash per share | 4.34 | 3.8 | 4 | 4.53 | 3.67 | |
Book value per share | 4.06 | 3.72 | 3.99 | 3.58 | 3.55 | |
Tangible book value per share | 4.06 | 3.72 | 3.99 | 3.58 | 3.55 | |
Share holders equity per share | 4.06 | 3.72 | 3.99 | 3.58 | 3.55 | |
Interest debt per share | 0.18 | 0.11 | 0.13 | 0.26 | 0.22 | |
Market cap | 96.26M | 125.09M | 257.76M | 188.09M | 94.18M | |
Enterprise value | 42.04M | 101.11M | 191.89M | 78.3M | -14.98M | |
P/E ratio | -1.84 | -2.42 | -3.77 | -2.71 | -1.21 | |
Price to sales ratio | 17.66 | 23.54 | 128.62 | 158.72 | 142.91 | |
POCF ratio | -5.45 | -6.32 | -14.21 | -9.41 | -4.32 | |
PFCF ratio | -5.38 | -6.27 | -14.2 | -9.41 | -4.27 | |
P/B Ratio | 0.65 | 0.93 | 1.64 | 1.21 | 0.55 | |
PTB ratio | 0.65 | 0.93 | 1.64 | 1.21 | 0.55 | |
EV to sales | 7.71 | 19.03 | 95.75 | 66.08 | -22.73 | |
Enterprise value over EBITDA | -2.82 | -6.62 | -9.78 | -4.01 | 0.69 | |
EV to operating cash flow | -2.38 | -5.11 | -10.58 | -3.92 | 0.69 | |
EV to free cash flow | -2.35 | -5.07 | -10.57 | -3.92 | 0.68 | |
Earnings yield | -0.14 | -0.1 | -0.07 | -0.09 | -0.21 | |
Free cash flow yield | -0.19 | -0.16 | -0.07 | -0.11 | -0.23 | |
Debt to equity | 0.04 | 0.04 | 0.03 | 0.07 | 0.06 | |
Debt to assets | 0.03 | 0.04 | 0.03 | 0.05 | 0.06 | |
Net debt to EBITDA | 3.64 | 1.57 | 3.36 | 5.63 | 5.05 | |
Current ratio | 7.44 | 10.12 | 13.38 | 10.41 | 12.58 | |
Interest coverage | -16.92 | 11.97 | 0 | 0 | 0 | |
Income quality | 1.25 | 1.39 | 1.06 | 1.15 | 1.12 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.9 | 0.99 | 2.66 | 5.09 | 12.58 | |
Research and developement to revenue | 2.87 | 2.93 | 7.57 | 1 | 21.2 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0.01 | |
Capex to revenue | -0.04 | -0.03 | 0 | 0 | -0.4 | |
Capex to depreciation | -1.1 | -0.66 | -0.02 | 0 | -0.86 | |
Stock based compensation to revenue | 0.34 | 0.38 | 0.94 | 1.69 | 2.66 | |
Graham number | 5.75 | 5.46 | 6.25 | 5.67 | 5.71 | |
ROIC | -0.09 | -0.1 | -0.1 | -0.11 | -0.12 | |
Return on tangible assets | -0.08 | -0.08 | -0.1 | -0.08 | -0.1 | |
Graham Net | 3.64 | 3.32 | 3.62 | 3.15 | 3.2 | |
Working capital | 138.51M | 127.23M | 148.64M | 181.36M | 164.46M | |
Tangible asset value | 146.97M | 135.02M | 156.7M | 155.34M | 169.76M | |
Net current asset value | 134.72M | 123.8M | 145.58M | 140.64M | 156.33M | |
Invested capital | 0.04 | 0.04 | 0.03 | 0.07 | 0.06 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.23M | 2.43M | 2.27M | 2.86M | 3.01M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 494.41 | 437.17 | 272.15 | 1.47K | 609.64 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.18 | 0.21 | 0.33 | 0.06 | 0.15 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.1 | -0.11 | -0.11 | -0.11 | |
Capex per share | -0.01 | 0 | 0 | 0 | -0.01 |
IKNA Frequently Asked Questions
What is Ikena Oncology, Inc. stock symbol ?
Ikena Oncology, Inc. is a US stock , located in Boston of Ma and trading under the symbol IKNA
What is Ikena Oncology, Inc. stock quote today ?
Ikena Oncology, Inc. stock price is $1.42 today.
Is Ikena Oncology, Inc. stock public?
Yes, Ikena Oncology, Inc. is a publicly traded company.